Navigation Links
Reportlinker Adds Emerging Opportunities in Biosimilar and Biobetter Drugs Markets
Date:1/4/2011

NEW YORK, Jan. 4, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Emerging Opportunities in Biosimilar and Biobetter Drugs Markets

http://www.reportlinker.com/p0357279/Emerging-Opportunities-in-Biosimilar-and-Biobetter-Drugs-Markets.html

Executive SummaryThe biosimilar and biobetter drugs market has started to position itself in a grand manner following a series of changes in regulatory framework in many countries. The biosimilar market segment represents a host of opportunities to the generics manufacturers to enter in a market, which is largely driven by commands premium prices and unmet needs. Backed by this feature, the market is continuing to outperform the global pharmaceutical market. "Emerging Opportunities in Biosimilar and Biobetter Drugs Markets" provides a detailed overview and a succinct, but deep-dive analysis on the biosimilar and biobetter drugs segments. The report discusses various exclusive features of biobetter drugs and studies their importance in meeting the future demand. It also highlights various emerging trends in the market and relates these with the future market growth.

The key objective of this report is to identify and probe into the emerging opportunities in the biobetter and biosimilar drugs market. It also tries to estimate the opportunities in various biological drugs segments including monoclonal antibodies, Erythropoietin and insulin, thus giving a complete idea about the market dynamics to the target audience of this report.

The report Emerging Opportunities in Biosimilar and Biobetter Drugs Markets also includes information on the key players in the industry and their product portfolio. This will enable the target audience of this report in understanding the contemporary industry scenario. Besides, the report gives complete information on various products whose patents are on the verge of expiration and thus, it is offering huge opportunities for generics manufacturers. Some of the key findings of report are given below:

  • The clause of "12 Year Exclusivity" for biologics in the US healthcare reform bill is going to have a long term impact on the growth of biosimilar drugs market
  • The increasing application of monoclonal antibodies in the cancer treatment is going to boost the demand of biosimilar and biobetter drugs in this market segment

  • Delivery TimeThree Business days

    To order this report:: Emerging Opportunities in Biosimilar and Biobetter Drugs Markets

    More  Market Research Report

    Check our  Company Profile, SWOT and Revenue Analysis!CONTACT:Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626
    '/>"/>

    SOURCE Reportlinker
    Copyright©2010 PR Newswire.
    All rights reserved

    Related biology technology :

    1. Reportlinker Adds Infectious Disease Molecular Diagnostic Testing
    2. Reportlinker Adds Smart Glass: Technologies and Global Markets Report
    3. Reportlinker Adds Synthetic Biology: Emerging Global Markets Report
    4. Reportlinker Adds Proteomics: Technologies and Global Markets Report
    5. Reportlinker Adds Nanomedicine Report
    6. Reportlinker Adds Small Molecule Kinase Inhibitors Report
    7. Reportlinker Adds Nanoporous Materials Report
    8. Reportlinker Adds Membrane Bioreactors Report
    9. Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement
    10. Reportlinker Adds High-Tech Patient Monitoring Systems Markets (Remote and Wireless Systems, Data Processing, EMR Data Transfer) Report
    11. Reportlinker Adds In Vitro Diagnostics in a Recession: IVD Market Forecasts, Analysis and Success Strategies Report
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/11/2017)... ... October 11, 2017 , ... Proscia ... be hosting a Webinar titled, “Pathology is going digital. Is your lab ready?” ... pathology adoption best practices and how Proscia improves lab economics and realizes an ...
    (Date:10/11/2017)... the Netherlands and LAGUNA HILLS, Calif. ... The Institute of Cancer Research, London ... use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients ... trial known as MUK nine . The University of ... trial, which is partly funded by Myeloma UK, and ICR ...
    (Date:10/11/2017)... ... 2017 , ... A new study published in Fertility and ... in vitro fertilization (IVF) transfer cycles. The multi-center matched cohort study ... comparing the results from the fresh and frozen transfer cohorts, the authors of ...
    (Date:10/10/2017)... ... ... San Diego-based team building and cooking events company, Lajollacooks4u, has unveiled a ... new look is part of a transformation to increase awareness, appeal to new markets ... It will also expand its service offering from its signature gourmet cooking classes and ...
    Breaking Biology Technology:
    (Date:4/4/2017)... 2017   EyeLock LLC , a leader of ... States Patent and Trademark Office (USPTO) has issued U.S. ... of an iris image with a face image acquired ... company,s 45 th issued patent. ... given the multi-modal biometric capabilities that have recently come ...
    (Date:3/30/2017)... , March 30, 2017 Trends, opportunities ... (physiological and behavioral), by technology (fingerprint, AFIS, iris recognition, ... recognition, and others), by end use industry (government and ... immigration, financial and banking, and others), and by region ... , Asia Pacific , and ...
    (Date:3/24/2017)... Controller General of Immigration from Maldives Mr. Mohamed Anwar and ... international IAIR Award for the most innovative high security ePassport and eGates  ... ... Maldives Immigration Controller General, Mr. Mohamed Anwar ... right) have received the IAIR award for the "Most innovative high security ...
    Breaking Biology News(10 mins):